close and back to page

Latest News

Latest News

The Health Warrior: Why Danai Gurira Is Helping Johnson & Johnson Fight HIV/AIDS

Gurira, an award-winning playwright and actress, has partnered with Johnson & Johnson

Nielsen Hosts First-Ever Black Employee Forum

If you watched the Global Citizen Festival, you may have been moved by the powerful call-to-action from award-winning playwright and actress Danai Gurira, who's partnered with Johnson & Johnson (No. 8 on the DiversityInc Top 50 Companies list) to help fight HIV/AIDS and show how working directly with communities to combat a health crisis has the potential to positively transform generations to come.


Specifically, Gurira's helping to share the moving story of Nyumbani, a village that became the first sustainable HIV/AIDS community in Africa, allowing nearly half of the children who live there—either because they are HIV-positive or have been orphaned by the disease—to make it to college.

Gurira has actually made it her life's mission to help bring awareness about communities devastated by the disease. She saw the rise of HIV first-hand growing up in southern Africa, and since then, she's received critical acclaim for co-writing and acting in "In the Continuum," a play about two women grappling with their recent HIV diagnoses.

To hear more about why she's partnering with Johnson & Johnson, check out this inspiring video.

Johnson & Johnson Chairman and CEO Alex Gorsky Takes the #EmbracingSustainability Challenge

A new Business Roundtable campaign is challenging America's top CEOs to shine a light on how they're doing their part to help improve the health of the environment.

Originally Published by Johnson & Johnson.

For more than 130 years, Johnson & Johnson has made it a mission to help keep people healthy. And since human health and environmental health are inextricably linked, the company is dedicated to helping keep the planet healthy, too.

Read More Show Less

Johnson & Johnson Human Performance Institute Expands Portfolio of C-suite Executive Development and Wellbeing Programs

The goal of Premier is to reinforce senior leaders and help them build personal resilience and character-centered leadership competencies that go beyond basic business skills-building.

REUTERS

Originally Published by Johnson & Johnson.

Johnson & Johnson Human Performance Institute (HPI) announced the expansion of its purpose-driven, character-centered executive development and wellbeing program, Premier Executive Leadership™ (Premier). HPI will now offer additional forms of its flagship Premier program, customized to cater to the unique needs and demands of the current, and next generation of global leaders. Gathering feedback and insights from CEOs, C-suite leaders and chief human resource officers around the globe, HPI uncovered an unmet need for highly personalized executive development programs that build and reinforce physical wellbeing, mental and emotional resilience, and character-centered leadership. This new offering expands upon the official launch of Premier last year.

Read More Show Less

Janssen Announces New Three-Year TREMFYA Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

At the three-year mark, patients receiving TREMFYA in clinical studies continue to show stably maintained PASI 90 and IGA 0/1 responses.

REUTERS

Originally Published by Johnson & Johnson.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new long-term data from the open-label period of the VOYAGE 1 clinical trial demonstrating that stably maintained rates of skin clearance with TREMFYA® treatment achieved from week 52 (1 year) were maintained through week 156 (3 years) among adult patients with moderate to severe plaque psoriasis. TREMFYA® is the first anti-interleukin (IL)-23 monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) and is administered by subcutaneous injection. The findings, presented at the 37th Fall Clinical Dermatology Conference in Las Vegas, Nevada, showed nearly 83 percent of patients receiving TREMFYA® in the Phase 3 VOYAGE 1 study maintained at least a 90 percent improvement in the Psoriasis Area Severity Index (PASI 90) response (near complete skin clearance), and an Investigator's Global Assessment (IGA) score of cleared (0) or minimal disease (1) at week 156.

Read More Show Less

Johnson & Johnson Announces 10-year Initiative to Help End Tuberculosis, the World's #1 Infectious Killer

J&J's goal is to save an estimated 1.8 million lives and prevent 12 million new TB infections.

REUTERS

Originally Published by Johnson & Johnson.

Ahead of the first-ever United Nations (UN) High-Level Meeting on Tuberculosis (TB), Johnson & Johnson yesterday announced a comprehensive 10-year initiative in support of the United Nations Sustainable Development Goal target of ending the TB pandemic by 2030. With the goal of saving an estimated 1.8 million lives and preventing 12 million new TB infections in the next decade, Johnson & Johnson will work with partners to improve detection of undiagnosed casesof TB, broaden access to its novel medicine for multidrug-resistant TB (MDR-TB), and accelerate research & development (R&D) to discover next-generation TB treatments.

Read More Show Less

Why Johnson & Johnson is on a Mission to Make Treating Pediatric Patients Safer

For Baby Safety Month, the company's Head of Pediatric Drug Development talks about the industry-leading Child Health Innovation Leadership Department.

REUTERS

Originally Published by Johnson & Johnson.

By Tamekia Reece

Ensuring the safety and well-being of children has been a cornerstone of Johnson & Johnson's work for over 100 years.

Today, the company helps provide treatments to millions of kids across the globe to address everything from tuberculosis to intestinal worm infections, so children can reach their full potential. It's just one facet of a larger commitment: help improve the health of future generations, or "GenH."

It's why Johnson & Johnson created the Child Health Innovation Leadership Department (CHILD), which is part of the company's Office of the Chief Medical Officer. The mission of CHILD is to help drive the creation of new and better policies around medical treatments for children, as well as uphold the safety and effectiveness of pediatric drugs.Another important facet of that commitment: help improve medical innovation for these little patients.

In honor of Baby Safety Month, we spoke to Samuel Maldonado, M.D., Head of Pediatric Drug Development and Vice President, Child Health Innovation Leadership Department, Johnson & Johnson, to learn more about the company's forward-thinking work for kids.

Read More Show Less

Johnson & Johnson: Janssen Submits Esketamine Nasal Spray New Drug Application to U.S. FDA for Treatment-Resistant Depression

"Of the nearly 300 million people who suffer from major depressive disorder worldwide, about one-third do not respond to currently available treatments. This represents a major unmet public health need."

REUTERS

Originally Published by Johnson & Johnson.

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for esketamine nasal spray. Janssen is seeking FDA approval of esketamine for treatment-resistant depression in adults.

Read More Show Less

Johnson & Johnson: New National Survey Uncovers the Surprising Impact that Knee and Hip Pain Has on Women's Emotional Well-Being

Seventy-six percent of women surveyed agreed that the effects of their joint pain go far beyond mobility, impacting many aspects of their life.

REUTERS

Originally Published by Johnson & Johnson.

While many who suffer from knee or hip pain know that it impacts their everyday activities, results from a new survey show the significant emotional impact of joint pain. This includes impact on romantic and social relationships, ability to pursue hobbies and overall mood. The survey of more than 500 women ages 45-65, including those who have had joint replacement surgery and those planning to have joint replacement surgery, revealed:

  • 90 percent of respondents agree that they are not able to live life to the fullest because of their joint pain,
  • Nine out of 10 respondents say their joint pain negatively impacts their mood,
  • Two-thirds of the respondents have avoided a social situation because of joint pain,
  • More than half of respondents said their joint pain makes it personally challenging to feel like a part of the family,
  • 89 percent of respondents feel like they can participate in their life again after joint replacement surgery,
  • Two out of three respondents who had joint replacement surgery say their relationship with their spouse or partner improved, with 60 percent of respondents reporting improved intimacy.
Read More Show Less

Johnson & Johnson Announces Chris DelOrefice as Vice President of Investor Relations

Mr. DelOrefice has been with Johnson & Johnson for 19 years and has most recently served as the CFO of the North America Hospital Medical Devices (MD) Business.

REUTERS

Originally Published by Johnson & Johnson.

Johnson & Johnson announced the appointment of Chris DelOrefice to Vice President of Investor Relations for Johnson & Johnson, effective August 13, 2018. Mr. DelOrefice will report to Mr. Joseph Wolk, Executive Vice President and Chief Financial Officer of the Company.

Read More Show Less